Previous 10 | Next 10 |
Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024 ...
2023-08-15 10:30:56 ET Applied Molecular Transport press release ( NASDAQ: AMTI ): Q2 GAAP EPS of -$0.44. Cash and cash equivalents. As of June 30, 2023, cash and cash equivalents were $22.5 million. For further details see: Applied Molecular Transport GAAP E...
Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT)...
2023-05-12 06:54:17 ET Applied Molecular Transport press release ( NASDAQ: AMTI ): Q1 GAAP EPS of -$0.71. As of March 31, 2023, cash and cash equivalents were $41.8 million. The company believes its cash and cash equivalents will be sufficient to allow the company to ...
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023. Recent Business Highlights Engaged MTS Health Partners, L.P....
2023-03-27 16:34:02 ET Applied Molecular Transport ( NASDAQ: AMTI ) is seeking strategic alternatives, and as part of a restructuring, has laid off ~57% of its workforce. The biopharma has hired MTS Health Partners as an advisor. Prior to the announcement after Monday'...
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base ...
2023-03-09 17:56:58 ET Applied Molecular Transport press release ( NASDAQ: AMTI ): Q4 GAAP EPS of -$0.58 beats by $0.01 . As of December 31, 2022, cash and cash equivalents were $61.1 million compared to $159.8 million for the year ended December 31, 2021. F...
Exploring strategic partnership options to advance AMT-101 for chronic pouchitis, an orphan indication with no FDA-approved products Evaluating next steps for the company's second clinical asset, AMT-126 SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Applied Mol...
New positive data demonstrate oral AMT-101’s gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no systemic exposure by design Translational analysis reveals IL-10 biological responses in both 3mg and 10mg dose arms SOUTH SAN FRANCISCO, Calif., March...
News, Short Squeeze, Breakout and More Instantly...
Applied Molecular Transport Inc. Company Name:
AMTI Stock Symbol:
NASDAQ Market:
Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo ...
NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...
NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...